Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease
Identifieur interne : 001968 ( Main/Corpus ); précédent : 001967; suivant : 001969Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease
Auteurs : Shigeki Hirano ; Thomas Eckert ; Toni Flanagan ; David EidelbergSource :
- Movement Disorders [ 0885-3185 ] ; 2009.
English descriptors
- KwdEn :
Abstract
Neuroimaging and modern computational techniques like spatial covariance analysis have contributed greatly to the understanding of neural system abnormalities in neurodegenerative disorders such as Parkinson's disease (PD). The application of network analysis to metabolic PET data obtained from patients with PD has led to the identification and validation of two distinct spatial covariance patterns associated with the motor and cognitive manifestations of the disease. Quantifying the activity of these patterns in individual subjects has provided an objective tool for the assessment of treatment efficacy and differential diagnosis. We have found that activity of the PD motor‐related network is modulated by antiparkinsonian treatments such as dopaminergic therapy, deep brain stimulation (DBS), and subthalamic nucleus (STN) gene therapy. By contrast, the cognitive‐related network is not altered by these interventions for PD motor symptoms. This pattern may however change in response to therapies targeting the cognitive symptoms of this disorder. Recent work has focused on the identification of specific network biomarkers for atypical parkinsonian conditions such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). These disease‐related patterns can potentially be used in an automated imaging‐based algorithm to classify patients with these disorders. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22541
Links to Exploration step
ISTEX:73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease</title><author><name sortKey="Hirano, Shigeki" sort="Hirano, Shigeki" uniqKey="Hirano S" first="Shigeki" last="Hirano">Shigeki Hirano</name><affiliation><mods:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Department of Molecular Neuroimaging, Molecular Imaging Center, National Institute of Radiological Studies, Inage‐ku, Chiba‐shi, Chiba, Japan</mods:affiliation></affiliation></author><author><name sortKey="Eckert, Thomas" sort="Eckert, Thomas" uniqKey="Eckert T" first="Thomas" last="Eckert">Thomas Eckert</name><affiliation><mods:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology II, University of Magdeburg, Magdeburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Flanagan, Toni" sort="Flanagan, Toni" uniqKey="Flanagan T" first="Toni" last="Flanagan">Toni Flanagan</name><affiliation><mods:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name><affiliation><mods:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22541</idno><idno type="url">https://api.istex.fr/document/73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001968</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease</title><author><name sortKey="Hirano, Shigeki" sort="Hirano, Shigeki" uniqKey="Hirano S" first="Shigeki" last="Hirano">Shigeki Hirano</name><affiliation><mods:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Department of Molecular Neuroimaging, Molecular Imaging Center, National Institute of Radiological Studies, Inage‐ku, Chiba‐shi, Chiba, Japan</mods:affiliation></affiliation></author><author><name sortKey="Eckert, Thomas" sort="Eckert, Thomas" uniqKey="Eckert T" first="Thomas" last="Eckert">Thomas Eckert</name><affiliation><mods:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology II, University of Magdeburg, Magdeburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Flanagan, Toni" sort="Flanagan, Toni" uniqKey="Flanagan T" first="Toni" last="Flanagan">Toni Flanagan</name><affiliation><mods:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name><affiliation><mods:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009">2009</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S725">S725</biblScope><biblScope unit="page" to="S731">S731</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36</idno><idno type="DOI">10.1002/mds.22541</idno><idno type="ArticleID">MDS22541</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>brain metabolism</term><term>differential diagnosis</term><term>positron emission tomography</term><term>treatment response</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neuroimaging and modern computational techniques like spatial covariance analysis have contributed greatly to the understanding of neural system abnormalities in neurodegenerative disorders such as Parkinson's disease (PD). The application of network analysis to metabolic PET data obtained from patients with PD has led to the identification and validation of two distinct spatial covariance patterns associated with the motor and cognitive manifestations of the disease. Quantifying the activity of these patterns in individual subjects has provided an objective tool for the assessment of treatment efficacy and differential diagnosis. We have found that activity of the PD motor‐related network is modulated by antiparkinsonian treatments such as dopaminergic therapy, deep brain stimulation (DBS), and subthalamic nucleus (STN) gene therapy. By contrast, the cognitive‐related network is not altered by these interventions for PD motor symptoms. This pattern may however change in response to therapies targeting the cognitive symptoms of this disorder. Recent work has focused on the identification of specific network biomarkers for atypical parkinsonian conditions such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). These disease‐related patterns can potentially be used in an automated imaging‐based algorithm to classify patients with these disorders. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Shigeki Hirano MD</name><affiliations><json:string>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</json:string><json:string>Current Address: Department of Molecular Neuroimaging, Molecular Imaging Center, National Institute of Radiological Studies, Inage‐ku, Chiba‐shi, Chiba, Japan</json:string></affiliations></json:item><json:item><name>Thomas Eckert MD</name><affiliations><json:string>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</json:string><json:string>Department of Neurology II, University of Magdeburg, Magdeburg, Germany</json:string></affiliations></json:item><json:item><name>Toni Flanagan MA</name><affiliations><json:string>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</json:string></affiliations></json:item><json:item><name>David Eidelberg MD</name><affiliations><json:string>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</json:string><json:string>Departments of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>positron emission tomography</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>brain metabolism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>differential diagnosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment response</value></json:item></subject><articleId><json:string>MDS22541</json:string></articleId><language><json:string>eng</json:string></language><abstract>Neuroimaging and modern computational techniques like spatial covariance analysis have contributed greatly to the understanding of neural system abnormalities in neurodegenerative disorders such as Parkinson's disease (PD). The application of network analysis to metabolic PET data obtained from patients with PD has led to the identification and validation of two distinct spatial covariance patterns associated with the motor and cognitive manifestations of the disease. Quantifying the activity of these patterns in individual subjects has provided an objective tool for the assessment of treatment efficacy and differential diagnosis. We have found that activity of the PD motor‐related network is modulated by antiparkinsonian treatments such as dopaminergic therapy, deep brain stimulation (DBS), and subthalamic nucleus (STN) gene therapy. By contrast, the cognitive‐related network is not altered by these interventions for PD motor symptoms. This pattern may however change in response to therapies targeting the cognitive symptoms of this disorder. Recent work has focused on the identification of specific network biomarkers for atypical parkinsonian conditions such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). These disease‐related patterns can potentially be used in an automated imaging‐based algorithm to classify patients with these disorders. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>6.702</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1423</abstractCharCount><pdfWordCount>4350</pdfWordCount><pdfCharCount>29407</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>196</abstractWordCount></qualityIndicators><title>Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>S731</last><first>S725</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S2</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22541</json:string></doi><id>73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential confict of interest: None reported.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease</title><author><persName><forename type="first">Shigeki</forename><surname>Hirano</surname></persName><roleName type="degree">MD</roleName><affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</affiliation><affiliation>Current Address: Department of Molecular Neuroimaging, Molecular Imaging Center, National Institute of Radiological Studies, Inage‐ku, Chiba‐shi, Chiba, Japan</affiliation></author><author><persName><forename type="first">Thomas</forename><surname>Eckert</surname></persName><roleName type="degree">MD</roleName><affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</affiliation><affiliation>Department of Neurology II, University of Magdeburg, Magdeburg, Germany</affiliation></author><author><persName><forename type="first">Toni</forename><surname>Flanagan</surname></persName><roleName type="degree">MA</roleName><affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</affiliation></author><author><persName><forename type="first">David</forename><surname>Eidelberg</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, 350 Community Drive, Manhasset, NY 11030, USA</p></note><affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</affiliation><affiliation>Departments of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S725">S725</biblScope><biblScope unit="page" to="S731">S731</biblScope></imprint></monogr><idno type="istex">73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36</idno><idno type="DOI">10.1002/mds.22541</idno><idno type="ArticleID">MDS22541</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Neuroimaging and modern computational techniques like spatial covariance analysis have contributed greatly to the understanding of neural system abnormalities in neurodegenerative disorders such as Parkinson's disease (PD). The application of network analysis to metabolic PET data obtained from patients with PD has led to the identification and validation of two distinct spatial covariance patterns associated with the motor and cognitive manifestations of the disease. Quantifying the activity of these patterns in individual subjects has provided an objective tool for the assessment of treatment efficacy and differential diagnosis. We have found that activity of the PD motor‐related network is modulated by antiparkinsonian treatments such as dopaminergic therapy, deep brain stimulation (DBS), and subthalamic nucleus (STN) gene therapy. By contrast, the cognitive‐related network is not altered by these interventions for PD motor symptoms. This pattern may however change in response to therapies targeting the cognitive symptoms of this disorder. Recent work has focused on the identification of specific network biomarkers for atypical parkinsonian conditions such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). These disease‐related patterns can potentially be used in an automated imaging‐based algorithm to classify patients with these disorders. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>positron emission tomography</term></item><item><term>Parkinson's disease</term></item><item><term>brain metabolism</term></item><item><term>differential diagnosis</term></item><item><term>treatment response</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-10-07">Received</change><change when="2009-02-19">Registration</change><change when="2009">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="145"><doi origin="wiley" registered="yes">10.1002/mds.v24.2s</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">S2</numbering></numberingGroup><coverDate startDate="2009">2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="120" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22541</doi><idGroup><id type="unit" value="MDS22541"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-10-07"></event><event type="manuscriptRevised" date="2009-01-09"></event><event type="manuscriptAccepted" date="2009-02-19"></event><event type="firstOnline" date="2009-10-28"></event><event type="publishedOnlineFinalForm" date="2009-10-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S725</numbering><numbering type="pageLast">S731</numbering></numberingGroup><correspondenceTo>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, 350 Community Drive, Manhasset, NY 11030, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22541.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="58"></count><count type="wordTotal" number="4481"></count></countGroup><titleGroup><title type="main" xml:lang="en">Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Metabolic Networks in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" currentRef="#curr1"><personName><givenNames>Shigeki</givenNames><familyName>Hirano</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Thomas</givenNames><familyName>Eckert</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Toni</givenNames><familyName>Flanagan</familyName><degrees>MA</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af3" corresponding="yes"><personName><givenNames>David</givenNames><familyName>Eidelberg</familyName><degrees>MD</degrees></personName><contactDetails><email>david1@nshs.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology II, University of Magdeburg, Magdeburg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Departments of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="curr1" countryCode="JP"><unparsedAffiliation>Department of Molecular Neuroimaging, Molecular Imaging Center, National Institute of Radiological Studies, Inage‐ku, Chiba‐shi, Chiba, Japan</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">positron emission tomography</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">brain metabolism</keyword><keyword xml:id="kwd4">differential diagnosis</keyword><keyword xml:id="kwd5">treatment response</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Neuroimaging and modern computational techniques like spatial covariance analysis have contributed greatly to the understanding of neural system abnormalities in neurodegenerative disorders such as Parkinson's disease (PD). The application of network analysis to metabolic PET data obtained from patients with PD has led to the identification and validation of two distinct spatial covariance patterns associated with the motor and cognitive manifestations of the disease. Quantifying the activity of these patterns in individual subjects has provided an objective tool for the assessment of treatment efficacy and differential diagnosis. We have found that activity of the PD motor‐related network is modulated by antiparkinsonian treatments such as dopaminergic therapy, deep brain stimulation (DBS), and subthalamic nucleus (STN) gene therapy. By contrast, the cognitive‐related network is not altered by these interventions for PD motor symptoms. This pattern may however change in response to therapies targeting the cognitive symptoms of this disorder. Recent work has focused on the identification of specific network biomarkers for atypical parkinsonian conditions such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). These disease‐related patterns can potentially be used in an automated imaging‐based algorithm to classify patients with these disorders. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential confict of interest: None reported.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Metabolic Networks in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Shigeki</namePart><namePart type="family">Hirano</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</affiliation><affiliation>Current Address: Department of Molecular Neuroimaging, Molecular Imaging Center, National Institute of Radiological Studies, Inage‐ku, Chiba‐shi, Chiba, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Eckert</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</affiliation><affiliation>Department of Neurology II, University of Magdeburg, Magdeburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Toni</namePart><namePart type="family">Flanagan</namePart><namePart type="termsOfAddress">MA</namePart><affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Eidelberg</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, Manhasset, New York, USA</affiliation><affiliation>Departments of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, New York, USA</affiliation><description>Correspondence: Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore‐Long Island Jewish Health System, 350 Community Drive, Manhasset, NY 11030, USA</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009</dateIssued><dateCaptured encoding="w3cdtf">2008-10-07</dateCaptured><dateValid encoding="w3cdtf">2009-02-19</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">5</extent><extent unit="references">58</extent><extent unit="words">4481</extent></physicalDescription><abstract lang="en">Neuroimaging and modern computational techniques like spatial covariance analysis have contributed greatly to the understanding of neural system abnormalities in neurodegenerative disorders such as Parkinson's disease (PD). The application of network analysis to metabolic PET data obtained from patients with PD has led to the identification and validation of two distinct spatial covariance patterns associated with the motor and cognitive manifestations of the disease. Quantifying the activity of these patterns in individual subjects has provided an objective tool for the assessment of treatment efficacy and differential diagnosis. We have found that activity of the PD motor‐related network is modulated by antiparkinsonian treatments such as dopaminergic therapy, deep brain stimulation (DBS), and subthalamic nucleus (STN) gene therapy. By contrast, the cognitive‐related network is not altered by these interventions for PD motor symptoms. This pattern may however change in response to therapies targeting the cognitive symptoms of this disorder. Recent work has focused on the identification of specific network biomarkers for atypical parkinsonian conditions such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). These disease‐related patterns can potentially be used in an automated imaging‐based algorithm to classify patients with these disorders. © 2009 Movement Disorder Society</abstract><note type="content">*Potential confict of interest: None reported.</note><subject lang="en"><genre>Keywords</genre><topic>positron emission tomography</topic><topic>Parkinson's disease</topic><topic>brain metabolism</topic><topic>differential diagnosis</topic><topic>treatment response</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>S2</number></detail><extent unit="pages"><start>S725</start><end>S731</end><total>7</total></extent></part></relatedItem><identifier type="istex">73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36</identifier><identifier type="DOI">10.1002/mds.22541</identifier><identifier type="ArticleID">MDS22541</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001968 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001968 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:73BCCFA00D05421E6A9486FFCAD2D8BD7FFBCA36
|texte= Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |